Company Update (NASDAQ:VRTX): FDA panel votes to expand use of Vertex cystic fibrosis drug

[Reuters] – Food and Drug Administration advisory panel on Tuesday voted 13-2 to recommend expanding approval of Vertex Pharmaceuticals Inc’s cystic fibrosis drug Kalydeco to include a wider range of patients with the . . . → Read More: Company Update (NASDAQ:VRTX): FDA panel votes to expand use of Vertex cystic fibrosis drug Similar Articles: Stock Update (NYSE:PFE): FDA panel votes to keep severe warning on Pfizer anti-smoking drug Stock Update (NYSE:BSX): FDA panel offers mixed view on Boston Scientific Watchman device Company Update (NYSE:UNH): UnitedHealth to buy doctor management company MedSynergies
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.